Back to mobile site

Jefferies on Kezar Life Sciences (KZR): acquisition 'valuation makes sense'

March 30, 2026 3:52 PM EDT Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Hold rating and $7.00 price target on Kezar Life Sciences (NASDAQ: KZR)The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login